Squire Patton Boggs has advised Elos Medtech AB, on the successful closing of the acquisition of Klingel Holding GmbH (Klingel) from private equity firm IK Partners and management.
The team advising Elos Medtech was led by Frankfurt Corporate partner Norman Wasse, and included Marion von Grönheim, Andreas Lehmann and Dagmar Nolden.
Elos Medtech is a leading development and production partner for medical devices and components, with a focus on dental and orthopedic implants and instruments. The company operates from facilities in Sweden, Denmark, China, and the US, with more than 650 employees and a turnover of approximately SEK 950 million. Elos Medtech has been listed on NASDAQ Stockholm AB since 1989.
Headquartered in Pforzheim, Germany, Klingel has been a leading European contract development and manufacturing organization (CDMO) in the field of precision technology with a strategic focus on medical technology for more than 30 years. With eight company locations in Southern Germany and Switzerland and around 950 employees across the group, Klingel specializes in the manufacture of high-precision parts and complex assemblies, implants and instruments for different applications in medical technology.
The collaboration between Elos Medtech and Klingel creates brings together over 1500 employees spread across 13 sites in six countries. This combined force makes the newly formed entity among the top 10 global players in the CDMO market, with strengthened R&D capabilities and new technology expertise.